Last updated: February 13, 2026
Overview of the Drug
The National Drug Code (NDC) 55724-0211 corresponds to a specific formulation of a pharmaceutical product. Based on available data, this NDC typically refers to Carboplatin Injection, 150 mg/15 mL. It is an oncology drug used for chemotherapy to treat ovarian, lung, and other cancers.
Market Landscape
Current Market Size and Key Players
- The global chemotherapy drug market is estimated at $20 billion in 2022, with targeted agents and traditional chemotherapies accounting for significant shares.
- Carboplatin formulations dominate a segment with estimated sales of approximately $3 billion annually worldwide.
- The primary manufacturers include brands developed by companies such as Johnson & Johnson (through its subsidiary, Janssen), Teva Pharmaceuticals, and Mylan.
Distribution and Usage Trends
- Oncology drugs like Carboplatin are used predominantly in outpatient infusion centers and hospitals.
- The growth rate of carboplatin utilization has averaged about 3-4% annually over the past five years, driven by expanding indications and combination therapies.
- Introduction of biosimilars and new combination protocols impact market dynamics.
Regulatory Status and Market Access
- Approved by the FDA since the 1980s; 1578 generic versions are available.
- Patent expiration for initial formulations occurred over a decade ago, leading to heightened competition and price erosion.
- Payers and insurers favor generics, placing downward pressure on prices.
Price Trends and Projections
| Year |
Average Price per Vial (USD) |
Notes |
| 2022 |
$140 |
Inclusive of wholesale acquisition cost (WAC) |
| 2023 |
$135 |
Slight decrease due to generic competition |
| 2024 |
$130 |
Continued downward trend |
| 2025 |
$125 |
Market stabilization amid new competitors |
Source: IQVIA, Redbook data, and industry price reports.
Factors Influencing Price Trajectories
- Generic Competition: The proliferation of biosimilars and generics has decreased the cost of production and retail prices.
- Manufacturing Costs: Slight increases in raw material costs may moderate price declines but are offset by competition.
- Regulatory Changes: Potential for biosimilar approval pathways may further expand generic options.
- Market Penetration: Expanded use in combination therapies may sustain demand, supporting stable or slightly higher prices.
Future Outlook
- The market for carboplatin, including formulations like NDC 55724-0211, will likely experience a gradual price decline through 2025.
- Price erosion could accelerate if new biosimilars achieve regulatory approval and market entry.
- Price projections for 2026 and beyond anticipate a stabilization around $120 per vial, assuming current competitive trends persist.
Key Considerations
- Manufacturers seeking higher margins will need to innovate or develop combination drugs.
- Payers are increasingly incentivizing the use of lower-cost generics.
- Market entry of newer agents with improved safety profiles may impact demand more than pricing.
Key Takeaways
- NDC 55724-0211 corresponds to carboplatin, a widely used chemotherapy agent.
- The market is mature, with extensive generic competition driving prices downward.
- Current average price is approximately $135 per vial, with a trend toward further reductions.
- Industry dynamics suggest prices will stabilize near $120-$125 over the next two years.
- Biosimilar entry and combination therapies can affect future market size and pricing.
FAQs
1. What are the main competitors for carboplatin formulations like NDC 55724-0211?
Multiple generics, biosimilars, and combination drugs competing on efficacy, safety, and cost.
2. How does patent status impact the pricing of this NDC?
The original patent expiration led to widespread generic availability, reducing prices due to increased competition.
3. Are there upcoming regulatory changes that could affect prices?
Yes, biosimilar pathways could facilitate new competitors, further lowering costs.
4. How does market demand for carboplatin influence future prices?
Stable or growing demand from expanding indications and combination therapies supports price stability despite competition.
5. What strategic considerations should manufacturers prioritize?
Focus on biosimilar development, cost management, and exploring combination therapies to maintain margins.
References
[1] IQVIA, Redbook, 2022-2023 industry reports.
[2] FDA drug approval archives.
[3] Global oncology drug market analysis, 2022.
